menu
    • menu
    [{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Carbohydrate","year":"2024","type":"Inapplicable","leadProduct":"2-hydroxypropyl-beta Cyclodextrin","moa":"||Cholesterol efflux","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laminar Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Carbohydrate","year":"2024","type":"Inapplicable","leadProduct":"2-hydroxypropyl-beta Cyclodextrin","moa":"||Cholesterol efflux","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laminar Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Carbohydrate","year":"2025","type":"Inapplicable","leadProduct":"2-hydroxypropyl-beta Cyclodextrin","moa":"||Cholesterol efflux","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laminar Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"LabCorp | Northern Institute for Cancer Research (Newcastle) | Theradis pharma | Lipodom Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LAM561","moa":"Cholesterol efflux","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laminar Pharma \/ LabCorp | Northern Institute for Cancer Research (Newcastle) | Theradis pharma | Lipodom Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Pharma \/ LabCorp | Northern Institute for Cancer Research (Newcastle) | Theradis pharma | Lipodom Therapeutics"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"LAM561","moa":"Cholesterol efflux","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laminar Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Specialized Medical Services (SMS)-Oncology BV | Royal Marsden NHS Foundation Trust | Northern Institute for Cancer Research (Newcastle) | Vall d'Hebron Institute of Oncology | Instituto Oncol\u00f3gico IMQ | Onkologikoa, San Sebasti\u00e1n.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"LAM561","moa":"Cholesterol efflux","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laminar Pharma \/ Specialized Medical Services (SMS)-Oncology BV | Royal Marsden NHS Foundation Trust | Northern Institute for Cancer Research (Newcastle) | Vall d'Hebron Institute of Oncology | Instituto Oncol\u00f3gico IMQ | Onkologikoa, San Sebasti\u00e1n.","highestDevelopmentStatusID":"7","companyTruncated":"Laminar Pharma \/ Specialized Medical Services (SMS)-Oncology BV | Royal Marsden NHS Foundation Trust | Northern Institute for Cancer Research (Newcastle) | Vall d'Hebron Institute of Oncology | Instituto Oncol\u00f3gico IMQ | Onkologikoa, San Sebasti\u00e1n."},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Hackensack Meridian Health | Dana-Farber Cancer Institute | Laminar Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LAM561","moa":"Cholesterol efflux","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laminar Pharma \/ Hackensack Meridian Health | Dana-Farber Cancer Institute | Laminar Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Laminar Pharma \/ Hackensack Meridian Health | Dana-Farber Cancer Institute | Laminar Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Laminar Pharma

    Menu

    Laminar Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Laminar Pharma

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Laminar Pharma

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-hydroxypropyl-beta Cyclodextrin,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Laminar Reports LAM561 Data in First-Line Glioblastoma MGMT-Methylated Patients

                            Details : LAM561 (2-hydroxyoleic acid) is an oral synthetic derivative of oleic. It is being evaluated in combination with TMZ & RT for the treatment of glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Carbohydrate

                            Upfront Cash : Inapplicable

                            March 05, 2025

                            Lead Product(s) : 2-hydroxypropyl-beta Cyclodextrin,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Laminar Pharma

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Laminar Pharma

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-hydroxypropyl-beta Cyclodextrin,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Laminar Completes Recruitment for LAM561 in Glioblastoma Trial

                            Details : LAM561 (2-hydroxyoleic acid) is an oral synthetic derivative of oleic. It is being evaluated in combination with TMZ & RT for the treatment of glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Carbohydrate

                            Upfront Cash : Inapplicable

                            June 11, 2024

                            Lead Product(s) : 2-hydroxypropyl-beta Cyclodextrin,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Laminar Pharma

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Laminar Pharma

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-hydroxypropyl-beta Cyclodextrin,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Laminar Pharmaceuticals Receives Approval to Advance LAM561 in Glioblastoma Trial

                            Details : LAM561 (2-hydroxyoleic acid), a synthetic oleic acid derivative, is being evaluated in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Carbohydrate

                            Upfront Cash : Inapplicable

                            March 05, 2024

                            Lead Product(s) : 2-hydroxypropyl-beta Cyclodextrin,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Laminar Pharma

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Laminar Pharma

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAM561

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hackensack Meridian Health | Dana-Farber Cancer Institute | Laminar Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors

                            Details : LAM561 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Glioma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 06, 2020

                            Lead Product(s) : LAM561

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hackensack Meridian Health | Dana-Farber Cancer Institute | Laminar Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Laminar Pharma

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Laminar Pharma

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAM561

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : LabCorp | Northern Institute for Cancer Research (Newcastle) | Theradis pharma | Lipodom Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LAM561 With RT and TMZ for Adults With Glioblastoma

                            Details : LAM561 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2020

                            Lead Product(s) : LAM561

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : LabCorp | Northern Institute for Cancer Research (Newcastle) | Theradis pharma | Lipodom Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Laminar Pharma

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Laminar Pharma

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAM561

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients

                            Details : LAM561 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 07, 2019

                            Lead Product(s) : LAM561

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Laminar Pharma

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Laminar Pharma

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAM561

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Specialized Medical Services (SMS)-Oncology BV | Royal Marsden NHS Foundation Trust | Northern Institute for Cancer Research (Newcastle) | Vall d'Hebron Institute of Oncology | Instituto Oncológico IMQ | Onkologikoa, San Sebastián.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours

                            Details : LAM561 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Glioma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 15, 2013

                            Lead Product(s) : LAM561

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Specialized Medical Services (SMS)-Oncology BV | Royal Marsden NHS Foundation Trust | Northern Institute for Cancer Research (Newcastle) | Vall d'Hebron Institute of Oncology | Instituto Oncológico IMQ | Onkologikoa, San Sebastián.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth